Similar articles

• Being sensitive: to specify when amino acid tracers accumulate in a brain lesion.

  Pichler R. Pichler R. J Nucl Med. 2013 May;54(5):826. doi: 10.2967/jnumed.113.122325. Epub 2013 Mar 27. J Nucl Med. 2013. PMID: 23536222 No abstract available.
• Discriminating ability of (18)F-FET PET for several cerebral neoplastic lesions.

  Kawada T. Kawada T. J Nucl Med. 2014 Jan;55(1):176. doi: 10.2967/jnumed.113.128231. Epub 2013 Nov 6. J Nucl Med. 2014. PMID: 24198384 No abstract available.
• Reply: discriminating ability of (18)F-FET PET for several cerebral neoplastic lesions.

  Langen KJ, Rapp M, Galldiks N, Reifenberger G, Floeth FW. Langen KJ, et al. J Nucl Med. 2014 Jan;55(1):176. doi: 10.2967/jnumed.113.134007. Epub 2013 Nov 6. J Nucl Med. 2014. PMID: 24198386 No abstract available.
• PET imaging of gliomas using novel tracers: a sleeping beauty waiting to be kissed.

  Kläsner BD, Krause BJ, Beer AJ, Drzezga A. Kläsner BD, et al. Expert Rev Anticancer Ther. 2010 May;10(5):609-13. doi: 10.1586/era.10.37. Expert Rev Anticancer Ther. 2010. PMID: 20469990 Review. No abstract available.
• Clinical value of O-(2-[(18)F]-fluoroethyl)-L-tyrosine positron emission tomography in patients with low-grade glioma.

  Rapp M, Floeth FW, Felsberg J, Steiger HJ, Sabel M, Langen KJ, Galldiks N. Rapp M, et al. Neurosurg Focus. 2013 Feb;34(2):E3. doi: 10.3171/2012.12.FOCUS12336. Neurosurg Focus. 2013. PMID: 23373448 Review.